Pfizer’s Trispecific Antibody Tilrekimig Shows Strong Phase 2 Results in Atopic Dermatitis

Event summary

  • Pfizer’s Phase 2 study of tilrekimig (PF-07275315) met its primary efficacy endpoint, showing statistically significant improvement in EASI-75 compared to placebo.
  • The highest dose of tilrekimig achieved a 51.9% placebo-adjusted EASI-75 response rate at Week 16.
  • Tilrekimig targets IL-4, IL-13, and TSLP, potentially offering a once-monthly treatment for Th2-mediated inflammatory diseases.
  • Pfizer plans to initiate a Phase 3 pivotal study for tilrekimig in atopic dermatitis later this year.

The big picture

Pfizer’s positive Phase 2 results for tilrekimig position the trispecific antibody as a potential first-in-class treatment for atopic dermatitis, leveraging a novel mechanism targeting IL-4, IL-13, and TSLP. The data suggest a competitive edge over existing biologics, which could expand Pfizer’s portfolio in chronic inflammatory diseases. The company’s plans to initiate Phase 3 trials this year signal confidence in tilrekimig’s clinical and commercial potential.

What we're watching

Clinical Efficacy
Whether tilrekimig’s trispecific mechanism can sustain superior efficacy over existing biologics in Phase 3 trials.
Regulatory Pathway
The pace at which Pfizer advances tilrekimig through Phase 3 and potential regulatory approvals.
Market Positioning
How tilrekimig’s once-monthly dosing could differentiate it in the competitive atopic dermatitis and asthma markets.